CA3060715C - PROCESSES FOR MANUFACTURING NIRAPARIB - Google Patents
PROCESSES FOR MANUFACTURING NIRAPARIBInfo
- Publication number
- CA3060715C CA3060715C CA3060715A CA3060715A CA3060715C CA 3060715 C CA3060715 C CA 3060715C CA 3060715 A CA3060715 A CA 3060715A CA 3060715 A CA3060715 A CA 3060715A CA 3060715 C CA3060715 C CA 3060715C
- Authority
- CA
- Canada
- Prior art keywords
- formula
- salt
- compound
- acid
- contacting
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C303/00—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides
- C07C303/32—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of salts of sulfonic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C303/00—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides
- C07C303/42—Separation; Purification; Stabilisation; Use of additives
- C07C303/44—Separation; Purification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D211/70—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D211/74—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/025—Boronic and borinic acid compounds
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762489415P | 2017-04-24 | 2017-04-24 | |
| US201762489387P | 2017-04-24 | 2017-04-24 | |
| US62/489,387 | 2017-04-24 | ||
| US62/489,415 | 2017-04-24 | ||
| PCT/US2018/029131 WO2018200517A1 (en) | 2017-04-24 | 2018-04-24 | Methods of manufacturing of niraparib |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA3060715A1 CA3060715A1 (en) | 2018-11-01 |
| CA3060715C true CA3060715C (en) | 2024-10-01 |
Family
ID=63919973
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3060715A Active CA3060715C (en) | 2017-04-24 | 2018-04-24 | PROCESSES FOR MANUFACTURING NIRAPARIB |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US11161834B2 (enExample) |
| EP (1) | EP3615513B1 (enExample) |
| JP (1) | JP7179014B2 (enExample) |
| KR (1) | KR102582624B1 (enExample) |
| CN (2) | CN118271233A (enExample) |
| AU (2) | AU2018258274C1 (enExample) |
| CA (1) | CA3060715C (enExample) |
| ES (1) | ES2926255T3 (enExample) |
| IL (1) | IL270068B (enExample) |
| MA (1) | MA48475A (enExample) |
| MX (1) | MX393879B (enExample) |
| SG (1) | SG11201909807TA (enExample) |
| TW (1) | TWI783993B (enExample) |
| WO (1) | WO2018200517A1 (enExample) |
| ZA (1) | ZA201906944B (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20240136T1 (hr) | 2016-06-29 | 2024-04-12 | Tesaro, Inc. | Metode liječenja raka jajnika |
| AU2018246214B2 (en) | 2017-03-27 | 2021-07-08 | Merck Sharp & Dohme Llc | Niraparib compositions |
| WO2018200517A1 (en) | 2017-04-24 | 2018-11-01 | Tesaro, Inc. | Methods of manufacturing of niraparib |
| TW202444417A (zh) | 2017-05-09 | 2024-11-16 | 美商提薩羅有限公司 | 治療癌症的組合療法 |
| CN110913911A (zh) | 2017-05-18 | 2020-03-24 | 特沙诺有限公司 | 用于治疗癌症的组合疗法 |
| CN111278433A (zh) | 2017-09-26 | 2020-06-12 | 特沙诺有限公司 | 尼拉帕尼制剂 |
| WO2019067978A1 (en) | 2017-09-30 | 2019-04-04 | Tesaro, Inc. | POLYTHERAPIES FOR THE TREATMENT OF CANCER |
| US11801240B2 (en) | 2017-10-06 | 2023-10-31 | Tesaro, Inc. | Combination therapies and uses thereof |
| US12297184B2 (en) | 2018-10-03 | 2025-05-13 | Tesaro, Inc. | Niraparib salts |
| CN112300074B (zh) * | 2019-08-02 | 2023-12-29 | 北京盈科瑞创新药物研究有限公司 | 一种吲唑甲酰胺类化合物及其制备方法和应用 |
| US20250352534A1 (en) | 2022-02-15 | 2025-11-20 | Tesaro, Inc. | Use of Niraparib for the Treatment of Brain Cancer |
| WO2024142096A1 (en) * | 2022-12-29 | 2024-07-04 | Dr. Reddy’S Laboratories Limited | Process for preparation of niraparib tosylate and its intermediates |
| WO2025017711A1 (en) * | 2023-07-20 | 2025-01-23 | Natco Pharma Limited | An improved process for the preparation of niraparib tosylate monohydrate |
Family Cites Families (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5605793A (en) | 1994-02-17 | 1997-02-25 | Affymax Technologies N.V. | Methods for in vitro recombination |
| US6335160B1 (en) | 1995-02-17 | 2002-01-01 | Maxygen, Inc. | Methods and compositions for polypeptide engineering |
| US5837458A (en) | 1994-02-17 | 1998-11-17 | Maxygen, Inc. | Methods and compositions for cellular and metabolic engineering |
| FI104465B (fi) | 1995-06-14 | 2000-02-15 | Valio Oy | Proteiinihydrolysaatteja allergioiden hoitamiseksi tai estämiseksi, niiden valmistus ja käyttö |
| DE69841075D1 (de) | 1997-04-23 | 2009-10-01 | Kaneka Corp | Deoxynukleinsäure welche ein Polypeptid mit stereoselektiver Transaminase Aktivität kodiert, sowie die Deoxynukleinsäure enthaltende Transformanden |
| IL136574A0 (en) | 1997-12-08 | 2001-06-14 | California Inst Of Techn | A method for forming a polynucleotide of desired properties |
| JP4221100B2 (ja) | 1999-01-13 | 2009-02-12 | エルピーダメモリ株式会社 | 半導体装置 |
| GB0004297D0 (en) | 2000-02-23 | 2000-04-12 | Ucb Sa | 2-oxo-1 pyrrolidine derivatives process for preparing them and their uses |
| AU4964101A (en) | 2000-03-30 | 2001-10-15 | Maxygen Inc | In silico cross-over site selection |
| KR20030092107A (ko) | 2001-04-24 | 2003-12-03 | 메사추세츠 인스티튜트 오브 테크놀로지 | 탄소-헤테로원자 및 탄소-탄소 결합을 형성하는 구리-촉매방법 |
| EP1403255A4 (en) | 2001-06-12 | 2005-04-06 | Sumitomo Pharma | RHO KINASE INHIBITORS |
| BRPI0515851A (pt) | 2004-09-29 | 2008-08-12 | Mitsubishi Pharma Corp | composto de pirimidona |
| US20090275619A1 (en) | 2006-04-03 | 2009-11-05 | BOUERES Julia | Amide Substituted Indazole and Benzotriazole Derivatives as Poly(ADP-Ribose)Polymerase (PARP) Inhibitors |
| CN101528711A (zh) | 2006-08-31 | 2009-09-09 | 先灵公司 | 可用作抗细菌剂的乙内酰脲衍生物 |
| BRPI0806245B1 (pt) | 2007-01-10 | 2022-01-25 | Msd Italia S.R.L. | Compostos de fórmula i e seus usos |
| EP2132322A4 (en) | 2007-03-02 | 2013-02-20 | Richmond Chemical Corp | METHOD FOR INCREASING YIELD AND IMPROVING PURIFICATION OF PRODUCTS FROM REACTIONS WITH TRANSAMINASE |
| AR065804A1 (es) * | 2007-03-23 | 2009-07-01 | Smithkline Beecham Corp | Compuesto de indol carboxamida, composicion farmaceutica que lo comprende y uso de dicho compuesto para preparar un medicamento |
| EP2152262A2 (en) | 2007-04-27 | 2010-02-17 | UCB Pharma, S.A. | New heterocyclic derivatives useful for the treatment of cns disorders |
| EP2240466B1 (en) | 2008-01-08 | 2015-07-29 | Merck Sharp & Dohme Limited | Pharmaceutically acceptable salts of 2-{4-[(3s)-piperidin-3- yl]phenyl} -2h-indazole-7-carboxamide |
| JP5707344B2 (ja) | 2009-02-26 | 2015-04-30 | コデクシス， インコーポレイテッド | トランスアミナーゼ生体触媒 |
| JP2010269667A (ja) | 2009-05-20 | 2010-12-02 | Alps Electric Co Ltd | 多回転角度検出装置 |
| US8932836B2 (en) | 2010-08-16 | 2015-01-13 | Codexis, Inc. | Biocatalysts and methods for the synthesis of (1R,2R)-2-(3,4-dimethoxyphenethoxy)cyclohexanamine |
| US8729102B2 (en) | 2010-11-30 | 2014-05-20 | Takeda Pharmaceutical Company Limited | Bicyclic compound |
| PH12013501557A1 (en) | 2011-02-08 | 2019-06-03 | Pfizer | Glucagon receptor modulator |
| US8802673B2 (en) | 2011-03-24 | 2014-08-12 | Hoffmann-La Roche Inc | Heterocyclic amine derivatives |
| US9073911B2 (en) | 2011-06-09 | 2015-07-07 | Hoffmann-La Roche Inc. | Pyrazole derivatives |
| EP2928473B1 (en) | 2012-12-07 | 2017-06-28 | Merck Sharp & Dohme Corp. | Regioselective n-2 arylation of indazoles |
| DK2928865T3 (en) | 2012-12-07 | 2018-06-18 | Merck Sharp & Dohme | BIOCATALYTIC TRANSAMINATION PROCEDURE |
| US20160160294A1 (en) | 2014-12-08 | 2016-06-09 | Tesaro | Methods and materials for predicting response to niraparib |
| HRP20240136T1 (hr) | 2016-06-29 | 2024-04-12 | Tesaro, Inc. | Metode liječenja raka jajnika |
| CN106496187A (zh) | 2016-09-14 | 2017-03-15 | 陕西科技大学 | 一种制备PARP抑制剂Niraparib的合成方法 |
| CN106432056A (zh) * | 2016-09-17 | 2017-02-22 | 青岛辰达生物科技有限公司 | 一种尼拉帕布中间体(3s)‑3‑(4‑氨基苯基)哌啶‑1‑甲酸叔丁酯的制备方法 |
| CN106432057A (zh) * | 2016-09-17 | 2017-02-22 | 青岛云天生物技术有限公司 | 一种制备(3s)‑3‑(4‑氨基苯基)哌啶‑1‑甲酸叔丁酯的方法 |
| CN106432055A (zh) * | 2016-09-17 | 2017-02-22 | 青岛辰达生物科技有限公司 | 一种尼拉帕布中间体4‑（哌啶‑3‑基）苯胺的制备方法 |
| EP3606523A1 (en) | 2017-03-27 | 2020-02-12 | Tesaro, Inc. | Niraparib formulations |
| AU2018246214B2 (en) | 2017-03-27 | 2021-07-08 | Merck Sharp & Dohme Llc | Niraparib compositions |
| WO2018200517A1 (en) | 2017-04-24 | 2018-11-01 | Tesaro, Inc. | Methods of manufacturing of niraparib |
| TW202444417A (zh) | 2017-05-09 | 2024-11-16 | 美商提薩羅有限公司 | 治療癌症的組合療法 |
| CN110913911A (zh) | 2017-05-18 | 2020-03-24 | 特沙诺有限公司 | 用于治疗癌症的组合疗法 |
| CN111278433A (zh) | 2017-09-26 | 2020-06-12 | 特沙诺有限公司 | 尼拉帕尼制剂 |
| WO2019067978A1 (en) | 2017-09-30 | 2019-04-04 | Tesaro, Inc. | POLYTHERAPIES FOR THE TREATMENT OF CANCER |
| US11801240B2 (en) | 2017-10-06 | 2023-10-31 | Tesaro, Inc. | Combination therapies and uses thereof |
| TW201929902A (zh) | 2017-12-27 | 2019-08-01 | 美商提薩羅有限公司 | 治療癌症之方法 |
| BR112020015909A2 (pt) | 2018-02-05 | 2020-12-15 | Tesaro, Inc. | Formulações pediátricas de niraparib e métodos de tratamento pediátrico |
-
2018
- 2018-04-24 WO PCT/US2018/029131 patent/WO2018200517A1/en not_active Ceased
- 2018-04-24 MX MX2019012658A patent/MX393879B/es unknown
- 2018-04-24 CN CN202410234039.3A patent/CN118271233A/zh active Pending
- 2018-04-24 TW TW107113922A patent/TWI783993B/zh active
- 2018-04-24 AU AU2018258274A patent/AU2018258274C1/en active Active
- 2018-04-24 JP JP2019557567A patent/JP7179014B2/ja active Active
- 2018-04-24 CA CA3060715A patent/CA3060715C/en active Active
- 2018-04-24 US US16/608,059 patent/US11161834B2/en active Active
- 2018-04-24 MA MA048475A patent/MA48475A/fr unknown
- 2018-04-24 ES ES18790167T patent/ES2926255T3/es active Active
- 2018-04-24 IL IL270068A patent/IL270068B/en unknown
- 2018-04-24 CN CN201880040321.0A patent/CN110753684A/zh active Pending
- 2018-04-24 KR KR1020197034673A patent/KR102582624B1/ko active Active
- 2018-04-24 SG SG11201909807T patent/SG11201909807TA/en unknown
- 2018-04-24 EP EP18790167.3A patent/EP3615513B1/en active Active
-
2019
- 2019-10-22 ZA ZA2019/06944A patent/ZA201906944B/en unknown
-
2021
- 2021-08-09 AU AU2021215116A patent/AU2021215116B2/en active Active
- 2021-10-29 US US17/452,928 patent/US11629137B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP3615513B1 (en) | 2022-07-20 |
| TWI783993B (zh) | 2022-11-21 |
| IL270068B (en) | 2022-06-01 |
| AU2018258274B2 (en) | 2021-05-13 |
| ZA201906944B (en) | 2023-03-29 |
| US11161834B2 (en) | 2021-11-02 |
| CA3060715A1 (en) | 2018-11-01 |
| JP7179014B2 (ja) | 2022-11-28 |
| US11629137B2 (en) | 2023-04-18 |
| CN110753684A (zh) | 2020-02-04 |
| EP3615513A1 (en) | 2020-03-04 |
| MA48475A (fr) | 2020-03-04 |
| AU2021215116A1 (en) | 2021-08-26 |
| US20220041575A1 (en) | 2022-02-10 |
| SG11201909807TA (en) | 2019-11-28 |
| AU2018258274C1 (en) | 2021-12-02 |
| NZ758948A (en) | 2024-04-26 |
| BR112019022320A2 (pt) | 2020-05-26 |
| US20200055837A1 (en) | 2020-02-20 |
| CN118271233A (zh) | 2024-07-02 |
| WO2018200517A1 (en) | 2018-11-01 |
| JP2020517668A (ja) | 2020-06-18 |
| AU2018258274A1 (en) | 2019-11-14 |
| ES2926255T3 (es) | 2022-10-24 |
| MX393879B (es) | 2025-03-24 |
| KR20200021456A (ko) | 2020-02-28 |
| EP3615513A4 (en) | 2020-12-09 |
| KR102582624B1 (ko) | 2023-09-22 |
| TW201841889A (zh) | 2018-12-01 |
| AU2021215116B2 (en) | 2022-12-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2021215116B2 (en) | Methods of Manufacturing of Niraparib | |
| CN105518005B (zh) | 作为rock抑制剂的三环吡啶-甲酰胺衍生物 | |
| CN105102448B (zh) | 作为rock1和rock2抑制剂的苯基吡唑衍生物 | |
| US10781211B2 (en) | Spirocycle compounds and methods of making and using same | |
| AU2022203557B2 (en) | Dual MAGL and FAAH inhibitors | |
| US10301306B2 (en) | Substituted dihydro-1H-pyrrolo[3,2-c]pyridin-4(5H)-ones as RIPK3 inhibitors | |
| NZ591878A (en) | Novel fused aminodihydrothiazine derivative | |
| WO2024064026A1 (en) | Akt1 modulators | |
| JP2022513151A (ja) | 重水素化大環状化合物の調製方法 | |
| CN111499640A (zh) | 哌嗪并三唑类衍生物的手性拆分方法 | |
| TWI454470B (zh) | 硫苯並薁丙酸衍生物之製造法 | |
| HK40025665A (en) | Methods of manufacturing of niraparib | |
| HK40025665B (en) | Methods of manufacturing of niraparib | |
| EA044378B1 (ru) | Способы изготовления нирапариба | |
| WO2022194087A1 (en) | Modified proteins and protein binders | |
| BR112019022320B1 (pt) | Processo para preparar niraparibe | |
| EP4359380A1 (en) | Processes for the preparation of (s)-2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl) methyl)benzyl) amino)isoindoline-1,3-dione |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20230619 |
|
| Q17 | Modified document published |
Free format text: ST27 STATUS EVENT CODE: A-4-4-Q10-Q17-Q103 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DOCUMENT PUBLISHED Effective date: 20240926 |
|
| F11 | Ip right granted following substantive examination |
Free format text: ST27 STATUS EVENT CODE: A-4-4-F10-F11-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: GRANT BY ISSUANCE Effective date: 20241001 |
|
| MPN | Maintenance fee for patent paid |
Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 7TH ANNIV.) - STANDARD Year of fee payment: 7 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250324 |
|
| R00 | Party data change recorded |
Free format text: ST27 STATUS EVENT CODE: A-4-4-R10-R00-R119 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REVOCATION OF AGENT REQUEST Effective date: 20250618 Free format text: ST27 STATUS EVENT CODE: A-4-4-R10-R00-R116 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPOINTMENT OF AGENT REQUEST Effective date: 20250618 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250625 |
|
| R17 | Change to representative recorded |
Free format text: ST27 STATUS EVENT CODE: A-4-4-R10-R17-R117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPOINTMENT OF AGENT REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250721 Free format text: ST27 STATUS EVENT CODE: A-4-4-R10-R17-R121 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REVOCATION OF AGENT REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250721 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250721 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250808 |